Chiesi Farmaceutici has been granted a patent for a pharmaceutical composition that exhibits delayed release properties when administered as tablets. The patent also covers a method for treating transfusional iron overload in patients with thalassemia syndromes by orally administering a specific tablet formulation. The tablet contains deferiprone and an enteric coating, allowing for twice daily administration that is equivalent to thrice daily administration of an immediate release tablet. GlobalData’s report on Chiesi Farmaceutici gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Chiesi Farmaceutici, Inhalation devices was a key innovation area identified from patents. Chiesi Farmaceutici's grant share as of September 2023 was 50%. Grant share is based on the ratio of number of grants to total number of patents.
Delayed release tablets for treating transfusional iron overload in thalassemia
A recently granted patent (Publication Number: US11723874B2) describes a method for treating transfusional iron overload in patients with thalassemia syndromes and sickle cell disease. The method involves orally administering a tablet to the patient. The tablet consists of a core and an enteric coating.
The core of the tablet includes 1000 mg of deferiprone, an enteric polymer (such as hydroxypropyl methylcellulose acetate succinate or HPMCAS), a pH adjusting agent, and a glidant. The core may also contain a lubricant, such as magnesium stearate. The enteric coating of the tablet includes a plasticizer, an anti-tacking agent, an opacifying agent, and an enteric polymer.
The tablet can be administered to the patient as whole tablets, half tablets, or a combination of both. The enteric polymer in the core and coating can be selected from various options, including HPMCAS, HPMC phthalate, polyvinyl acetate phthalate, methacrylic acid copolymers, and their derivatives. The pH adjusting agent in the core can be meglumine, metal oxides, metal hydroxides, basic salts of weak acids, or a combination thereof.
The method also allows for the inclusion of a lubricant in the core, such as magnesium stearate, calcium stearate, stearic acid, sodium stearyl fumarate, talc, or a combination thereof. The tablet can be administered in a dosage range of 50 mg/kg/day to about 100 mg/kg/day.
In summary, this patent describes a method for treating transfusional iron overload in patients with thalassemia syndromes and sickle cell disease. The method involves orally administering a tablet that contains specific components in the core and enteric coating. The tablet can be administered in various forms and dosages, providing a potential treatment option for patients with these conditions.
To know more about GlobalData’s detailed insights on Chiesi Farmaceutici, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
